Correction to: Diabetes Ther https://doi.org/10.1007/s13300-019-0657-8
In the original publication, Table 2 note was incorrectly published as “*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2”.
The correct text should read as “*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with an SGLT2i therapy who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2.”
The original article has been corrected.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Ali, A., Bain, S., Hicks, D. et al. Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. Diabetes Ther 10, 1623–1624 (2019). https://doi.org/10.1007/s13300-019-0670-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-019-0670-y